Article
Regulatory Harmonization for Biologics — FDA BLA vs. EMA MAA vs. PMDA NDA: The CMC Module 3 Differences
Your monoclonal antibody BLA passed FDA's CMC review without a comparability deficiency after your Phase 2 process change. Your EMA MAA was filed simultaneously with the same comparability…
XGene Articles & Analysis
Evidence-led analysis for decisions that matter.
Senior-authored regulatory, CMC, GMP, quality, and inspection analysis designed for practical use—not passive reading.
01SignalSource evidence
02InterpretTechnical judgment
03ApplyDecision pathway
Publication library
Keep moving from evidence to decision.
Article
Regulatory Harmonization for Biologics — FDA BLA vs. EMA MAA vs. PMDA NDA: The CMC Module 3 Differences
Your monoclonal antibody BLA passed FDA's CMC review without a comparability deficiency after your Phase 2 process change. Your EMA MAA was filed simultaneously with the same comparability…
Article
ICH Q11 Starting Material Justification — Global Convergence and Remaining Regulatory Differences
ICH Q11 was designed to harmonize starting material selection for drug substances globally. FDA, EMA, and PMDA all implement it. They do not implement it identically.
Article
Mutual Recognition Agreements — What the FDA-EMA MRA Means for GMP Inspection and CMC Strategy
The FDA-EU MRA for GMP inspections has been fully operational since 2019. Years later, most pharmaceutical companies still haven't updated their FDA inspection readiness strategy to account for…
Article
EMA Scientific Advice vs. FDA Pre-Submission Meetings — How the Two Systems Differ for CMC Strategy
EMA scientific advice is not a regulatory commitment. The SAWP advice document says so explicitly — and the CHMP reviewer who assesses your MAA Module 3 has not…
Article
WHO Prequalification CMC — The Technical Dossier Requirements for Global Access and Procurement Programs
Your FDA ANDA approval demonstrates cGMP manufacturing and bioequivalent performance to the FDA reference listed drug. WHO Prequalification assessors will not use it as the basis for WHO…
Article
TGA Australia CMC Pathways — ARTG and the Module 3 Requirements Under Australian Therapeutic Goods Regulation
The abridged TGA evaluation pathway accepts your FDA NDA approval. It does not waive the Module 3 deficiencies TGA will find in your FDA-approved CMC dossier.
Article
ANVISA Brazil CMC Requirements — Registration Dossier and Technical Requirements for Drug Products
Brazil is the largest pharmaceutical market in Latin America and one of the most exacting. ANVISA's registration system has adopted the ICH CTD structure — but it has…
Article
ICH Q8 Q9 Q10 Global Implementation — Convergence and Remaining Gaps Across FDA, EMA, and PMDA
ICH Q8, Q9, and Q10 represent the most successful pharmaceutical regulatory harmonization initiative in history — and also one of the most consistently misunderstood.
Article
EMA CMC Review Process — The CHMP Assessment Report and What CMC Deficiency Letters Look Like
The EMA CHMP centralized procedure has a 210-day review clock, but it has never taken 210 days for an applicant to discover what a Major Objection on quality…
Article
ICH Common Technical Document — Regional Module 3 Variations That Affect Your Global Regulatory Strategy
The ICH CTD format harmonized the structure of global drug regulatory submissions. It did not harmonize what goes inside them.
Article
Health Canada CMC Review — CTA and NDS CMC Expectations vs. IND and NDA Requirements
Health Canada operates under the same ICH CTD framework and uses the same ICH guideline set as FDA. None of that means a Health Canada CTA CMC package…
Article
PMDA CMC Requirements — Japan New Drug Application and the Differences That Catch US-Centric Programs
An FDA-approved NDA is not a J-NDA CMC package. The ICH CTD format is common. The regulatory expectations are not.
Read with purpose
Every analysis should make the next move clearer.
- 01ReadUnderstand the technical argument.
- 02TraceFollow evidence and regulatory context.
- 03CompareExplore related XGene intelligence.
- 04ActConnect the issue to a practical pathway.